Amyloid-Targeting Class of Alzheimer Disease Drugs Show Potential, Raise Concerns of Accessibility for Diverse Patients

Advancements in the development of amyloid-targeting monoclonal antibodies show promise for treating Alzheimer disease, but there have been concerns around cost, adverse reactions, and inequity of care for marginalized patients.

Related Keywords

United States ,Alaska ,American ,Americans ,Alaskan , ,Kaiser Family Foundation ,Alzheimer Association ,Damicoa Health ,National Coverage Determination ,Clinical Dementia Rating Sum ,Native American ,Alaskan Native ,